98%
921
2 minutes
20
The treat-to-target approach is a concept that has been successfully implemented in many disease areas such as rheumatoid arthritis and cardiovascular disease and more recently is being discussed in asthma. Currently, asthma management is focused on severity of symptoms and disease control, with treatment approaches tailored to these symptoms versus the underlying disease activity. Although successful in many patients, there are limitations to this approach, because treatments targeting the underlying pathophysiology of disease may not be initiated until later in a patient's disease trajectory. This can leave patients with uncontrolled asthma despite high treatment doses, or initiating these treatments after long-term lung function decline has occurred. Implementing a treat-to-target approach in asthma that focuses on remission as a treatment goal advocates for a more personalized treatment approach in which the remission target offers patients and clinicians a clear benchmark for the best possible outcomes, and treatments that target the underlying pathophysiology of disease are initiated earlier in the disease course, to optimize long-term outcomes and prevent irreversible lung function decline.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jaip.2025.05.012 | DOI Listing |
Front Med (Lausanne)
August 2025
Department of Global Public Health and Primary Care, Bergen Center for Ethics and Priority Settings (BCEPS), Bergen, Norway.
Rheumatoid arthritis is a chronic inflammatory joint disease with low treatment coverage in sub-Saharan Africa. Effective treatment strategies are available. We aimed to evaluate the cost effectiveness of six disease modifying anti-rheumatic drug (DMARD) treat-to-target treatment strategies for patients with rheumatoid arthritis in Zanzibar.
View Article and Find Full Text PDFDiabetes Obes Metab
September 2025
Embla ApS, Copenhagen, Denmark.
Aims: To evaluate the effectiveness of an online multidisciplinary weight loss service combining individualised semaglutide dosing with intensive behavioural therapy (IBT) in adults living with overweight or obesity.
Materials And Methods: This retrospective cohort study included data from Danish participants enrolled in a digital weight loss programme via the Embla app between January 2022 and September 2024. The programme offered semaglutide with personalised dosing alongside evidence-based recommendations on nutrition, exercise and habits, delivered through IBT.
J Rheumatol
September 2025
K. Callis Duffin, MD, MS, Department of Dermatology, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, Utah, USA.
Rheumatologists and other nondermatologists often encounter patients with psoriatic arthritis (PsA) who present with cutaneous diseases that mimic psoriasis (PsO). Cutaneous disorders including tinea, seborrheic dermatitis, eczema, pityriasis rubra pilaris, syphilis, or cutaneous lymphoma are commonly mistaken for PsO. It is crucial for rheumatologists and other nondermatologists to recognize alternative conditions and to consider referral to dermatology when skin disease is not responding to therapy.
View Article and Find Full Text PDFJ Manag Care Spec Pharm
September 2025
Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora.
Background: Gouty arthritis affects 3.9% of American adults and can be effectively managed using urate-lowering therapy initiated at a low dose and titrated to achieve a serum urate of less than 6 mg/dL, the "treat-to-target" approach. This approach is often underused in primary care (PC) settings.
View Article and Find Full Text PDFRheumatology (Oxford)
August 2025
Department of Rheumatology, Erasmus MC, Rotterdam, The Netherlands.
Objectives: To investigate whether clinical outcomes and patient reported outcomes (PROs) differ over 2 years based on the age of onset of rheumatoid arthritis (RA).
Methods: All RA patients from the tREACH trial, a multicenter, stratified, single-blinded trial with a treat-to-target management approach and a fixed medication protocol were included. The age of disease onset was categorized into young-onset RA (YORA) (<45 years, n = 119); middle-aged onset RA (MORA) (45-65 years, n = 208); and elderly-onset RA (EORA) (>65 years, n = 98) at the time of diagnosis.